menu
    • menu
    [{"orgOrder":0,"company":"Dexcel Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"ISRAEL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Chlorhexidine","moa":"Cell membrane","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Dexcel Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dexcel Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dexcel Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Dexcel Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"ISRAEL","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Dental and Oral Health","graph2":"Phase III","graph3":"Dexcel Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Implant","sponsorNew":"Dexcel Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dexcel Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Dexcel Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"ISRAEL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Dental and Oral Health","graph2":"Phase III","graph3":"Dexcel Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dexcel Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dexcel Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Dexcel Pharma","sponsor":"SK Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABA-A receptor; anion channel | Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Dexcel Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Dexcel Pharma \/ SK Biopharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Dexcel Pharma \/ SK Biopharmaceuticals"},{"orgOrder":0,"company":"Dexcel Pharma","sponsor":"Dexcel Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lercanidipine","moa":"Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Dexcel Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dexcel Pharma \/ Dexcel Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Dexcel Pharma \/ Dexcel Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Dexcel Pharma

    Menu

    Dexcel Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dexcel Pharma

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Dexcel Pharma

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cenobamate

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : SK Biopharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SK Biopharmaceuticals’ epilepsy drug cenobamate OKed in Israel

                            Details : Dexcel holds exclusive commercialization rights to Xcopri (cenobamate), is an antiseizure medication for epilepsy in Israel.

                            Product Name : Xcopri

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            May 03, 2023

                            Lead Product(s) : Cenobamate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : SK Biopharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Dexcel Pharma

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Dexcel Pharma

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chlorhexidine Gluconate

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Efficacy and Safety of Chlorhexidine Gluconate Chip (PerioChip®) in Therapy of Peri-implantitis

                            Details : Chlorhexidine Gluconate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Peri-Implantitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 06, 2014

                            Lead Product(s) : Chlorhexidine Gluconate

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Dexcel Pharma

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Dexcel Pharma

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chlorhexidine Gluconate

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Efficacy and Safety of 2.5 mg Chlorhexidine Gluconate Chip (PerioChip®) in Frequent Treatment Versus Ro...

                            Details : Chlorhexidine Gluconate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Periodontitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 30, 2010

                            Lead Product(s) : Chlorhexidine Gluconate

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Dexcel Pharma

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Dexcel Pharma

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lercanidipine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Recipient : Meir Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Antihypertensive Efficacy of Fixed Combination Drug

                            Details : Lercanidipine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypertension.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 29, 2010

                            Lead Product(s) : Lercanidipine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Recipient : Meir Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Dexcel Pharma

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Dexcel Pharma

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chlorhexidine

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Efficacy and Safety of Chlorhexidine Gluconate Chip (Periochip®) in Therapy of Symptoms in Patients Wit...

                            Details : Chlorhexidine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Peri-Implantitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 03, 2010

                            Lead Product(s) : Chlorhexidine

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth